论文部分内容阅读
目的研究普伐他汀对急性冠脉综合征患者血浆一氧化氮、[凝血]因子Ⅰ、D-二聚体水平的影响。方法随机选择急性冠脉综合征患者135例,入选病人随机单盲分为普伐他汀组69例,常规治疗组66例,另外随机选择50例正常人做对照组。采用比色法测定一氧化氮含量;血凝仪法测定[凝血]因子Ⅰ含量;胶体金法测定D-二聚体含量。结果急性冠脉综合征患者血浆一氧化氮水平明显下降,与对照组比较差异有显著性(P<0.01);血浆纤维蛋白原、D-二聚体水平明显升高,与对照组比较差异有显著性(P<0.01);普伐他汀组和常规治疗组两组治疗前3者水平比较差异无显著性(P>0.05)。普伐他汀组治疗后一氧化氮水平较前明显升高,[凝血]因子Ⅰ、D-二聚体水平较前明显降低,与治疗前比较差异有显著性(P<0.01),与常规治疗组治疗后比较差异也有显著性(P<0.01);结论普伐他汀可通过保护血管内皮功能及改善血液流变学状态,从而改善心肌供血,抑制急性冠脉综合征的发生发展过程。
Objective To study the effects of pravastatin on the levels of plasma nitric oxide, [clotting] factor I and D-dimer in patients with acute coronary syndrome. Methods A total of 135 patients with acute coronary syndrome were randomly selected. The patients were randomly divided into pravastatin group (69 cases) and conventional treatment group (66 cases). Another 50 normal subjects were randomly selected as the control group. The contents of nitric oxide were determined by colorimetric method. The content of [coagulation] factor Ⅰ was determined by hemagglutination assay and D-dimer was determined by colloidal gold method. Results The levels of plasma nitric oxide in patients with acute coronary syndrome were significantly lower than those in the control group (P <0.01), and the levels of plasma fibrinogen and D-dimer were significantly higher than those in the control group (P <0.01). There was no significant difference between the two groups before and after pravastatin treatment (P> 0.05). The levels of nitric oxide in pravastatin group were significantly higher than those before treatment, and the levels of [clotting] factor I and D-dimer were significantly lower than those before treatment (P <0.01). Compared with the conventional treatment (P <0.01). Conclusions Pravastatin can improve myocardial blood supply and inhibit the occurrence and development of acute coronary syndrome by protecting vascular endothelial function and improving the blood rheology.